Study to Weigh the Effect of Exercise Training on BONE (SWEET-BONE) Quality and Strength in Type 2 Diabetes
NCT ID: NCT02421393
Last Updated: 2024-03-22
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
NA
Total Enrollment
200 participants
Study Classification
INTERVENTIONAL
Study Start Date
2018-10-01
Study Completion Date
2024-03-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Type 2 diabetes mellitus (T2DM) is associated with increased fracture risk despite normal to increased bone mass, thus suggesting poor bone quality. This study is aimed at weighing the effect of an exercise intervention program on parameters of bone quality in patients with type 2 diabetes mellitus. Two hundred patients with T2DM will be randomized to supervised exercise training on top of standard care (exercise, EXE, group; n=100) versus standard care (control, CON, group; n=100) for 24 months.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of Different Exercise Training Dose on Exercise Performance and Noninvasively Estimated Muscle Oxygen Extraction in Diabetic Postmenopausal Women
NCT00905203
Postmenopausal Diabetes
UNKNOWN
NA
Effects of 12- Weeks of Quantitative Weight-bearing Progressive Resistance Exercise Training on Glycemia Control and Improving Muscle Strength With Type 2 Diabetes Combine Pre-sarcopenia.
NCT04647617
Twelve Week Quantitative Weight Bearing of Resistance Training Effect on Glycemic Control and Muscle Strength
COMPLETED
NA
Cadence and Intensity in Adults With Type 2 Diabetes
NCT03940937
Type 2 Diabetes Mellitus
Walking
UNKNOWN
Physical Activity Assessment of Patients With Diabetic Foot Wounds
NCT04582357
Diabetic Foot
WITHDRAWN
NA
Optimization of Interval-training in Patients With Type 2 Diabetes
NCT02601482
Diabetes Mellitus, Type 2
UNKNOWN
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Type 2 diabetes mellitus (T2DM) is associated with increased fracture risk despite normal to increased bone mass, as assessed as bone mineral density (BMD) by dual-energy X-ray absorptiometry (DXA). Increased fracture risk remains after adjustment for BMD, and also falls, which are more frequent in these individuals than in their non-diabetic counterparts, due to chronic complications and treatments, and for body mass index, which seems to be protective through an increase in BMD. This suggests that patients with T2DM have poor bone quality, i.e. altered bone geometry and microarchitecture, which results in reduced strength. Based on the mechanostat therapy, physical activity (PA)/exercise would be beneficial for preventing fractures in T2DM individuals through greater mechanical loading on the skeleton, which causes favorable bone adaptations, and also by increasing muscle mass, strength, and performance, which reduces the risk of falls by improving gait and balance.
The aim of this study is to assess the effects of a specific exercise training intervention program on parameters of bone quality in patients with type 2 diabetes.
Two hundred patients with T2DM will be randomized to supervised exercise training on top of standard care (exercise, EXE, group; n=100) versus standard care (control, CON, group; n=100) for 24 months.
Sample size calculation is based on a recent report showing that TBS is lower in diabetic vs. control subjects (1.228 vs. 1.298) with a standard deviation of 0.140. To observe a normalization of TBS in EXE participants with a statistical power of 90% (α=0.05) by unpaired t-test, 85 patients per arm are needed (170 total). A sample size of 200 patients will allow to support a dropout rate up to 15%.
A sample of 100 non-diabetic subjects matched 1:2 by age, gender, and BMI will be used as controls for baseline measures.
EXE participants will attend two weekly sessions of 75 min each, supervised by an exercise specialist in a dedicated gym facility. Each session will include: 5 min of warm up; 20 min of aerobic training using treadmill; 15 min of resistance training of muscle groups of skeletal sites of fragility fractures; 15 min of "weight bearing" exercises using weighted vests; 8 min of core stability training; 8 min of balance training; and 4 min of flexibility training. Weighted vest worn also during aerobic training and any occupational, home and leisure-time PA.
CON subjects will receive advises to maintain a physically active lifestyle, according to current guidelines, by performing any type of commuting, occupational, home and leisure-time PA.
All patients will be subjected to a treatment regimen aimed at achieving optimal glycemic, lipid, BP and body weight targets, as established by current guidelines and including glucose-, lipid- and BP-lowering agents as needed. For ethical reasons, drugs will be also adjusted throughout the study to attain target levels and to account for reduced needs. Since all patients are overweight or obese, caloric intake (55% complex carbohydrates, 30% fat, and 15% protein) will be reduced to obtain a negative balance of 500 kcal/day. Requirements will be calculated by adding the estimated energy expenditure from PA to basal metabolism. Adherence to diet will be verified by the use of food diaries and dietary prescriptions will be adjusted at each intermediate visit. Patients with vitamin D levels ranging from 10 to 20 ng/dl will be treated with cholecalciferol 25.000 IU every 2 weeks for 2 months, then with cholecalciferol 25.000 IU every months, whereas those with vitamin D levels ranging from 20 to 30 ng/dl will be given cholecalciferol 25.000 IU every month. At 6 months participants, will be re-evaluated and treatment will be discontinued in case of vitamin D values \>30 ng/dl or continued for additional 6 months at the doses indicated above, and so on until the end of the study.
Randomization will be stratified by gender (males versus females), age (65-70 versus 71-75) and type of diabetes treatment (non-insulin versus insulin), using a permuted-block randomization software. Physicians and patients will not be blinded to group assignment, at variance with operators executing instrumental procedures, whereas sample blinding at central laboratory will be achieved using bar codes.
The primary endpoint is the trabecular bone score (TBS), which is derived from the antero-posterior spine raw DXA image(s) from the same region of interest as the BMD measurement by the use of a specific software and correlates with three-dimensional bone micro-architecture parameters. Among the numerous potential measures of bone quality, TBS is the only one that has been consistently shown to be lower in T2DM vs. control subjects.
Secondary endpoints include:
1. other potential measures of bone quality as assessed by peripheral quantitative computed tomography (pQCT) and quantitative ultrasound (QUS);
2. bone mass (BMD as assessed by DXA);
3. bone metabolism (sclerostin and other biochemical markers of bone formation and resorption);
4. body composition (total body lean and fat mass by total body DXA);
5. muscle strength (by dynamometer);
6. muscle mass/density (by pQCT);
7. balance, gait and power (by Short Battery Performance Test);
8. musculoskeletal (MS) symptoms (by questionnaire);
h. number of falls (by questionnaire); i. symptomatic and asymptomatic fractures (by history or medical records and vertebral morphometry, respectively).
Other measures include:
* quality of life (QoL);
* cardiorespiratory fitness;
* flexibility;
* volume of PA;
* coronary heart disease 10-year risk score.
Dietary intake and adverse events will be also recorded. Participants from both groups will be followed for additional 5 years in order to record the number of falls and eventual fractures during this time period. PA and MS symptoms will be also monitored throughout this 5-year interval. To this end, patients will be seen yearly (or every 6 months according to the degree of glycemic control and the overall cardiovascular risk profile) in order to collect self-report data on number of falls and type and amount of PA from a daily diary, clinical documentation on eventual fractures, and MS questionnaire.
The aim of this study is to assess the effects of a specific exercise training intervention program on parameters of bone quality in patients with type 2 diabetes.
Two hundred patients with T2DM will be randomized to supervised exercise training on top of standard care (exercise, EXE, group; n=100) versus standard care (control, CON, group; n=100) for 24 months.
Sample size calculation is based on a recent report showing that TBS is lower in diabetic vs. control subjects (1.228 vs. 1.298) with a standard deviation of 0.140. To observe a normalization of TBS in EXE participants with a statistical power of 90% (α=0.05) by unpaired t-test, 85 patients per arm are needed (170 total). A sample size of 200 patients will allow to support a dropout rate up to 15%.
A sample of 100 non-diabetic subjects matched 1:2 by age, gender, and BMI will be used as controls for baseline measures.
EXE participants will attend two weekly sessions of 75 min each, supervised by an exercise specialist in a dedicated gym facility. Each session will include: 5 min of warm up; 20 min of aerobic training using treadmill; 15 min of resistance training of muscle groups of skeletal sites of fragility fractures; 15 min of "weight bearing" exercises using weighted vests; 8 min of core stability training; 8 min of balance training; and 4 min of flexibility training. Weighted vest worn also during aerobic training and any occupational, home and leisure-time PA.
CON subjects will receive advises to maintain a physically active lifestyle, according to current guidelines, by performing any type of commuting, occupational, home and leisure-time PA.
All patients will be subjected to a treatment regimen aimed at achieving optimal glycemic, lipid, BP and body weight targets, as established by current guidelines and including glucose-, lipid- and BP-lowering agents as needed. For ethical reasons, drugs will be also adjusted throughout the study to attain target levels and to account for reduced needs. Since all patients are overweight or obese, caloric intake (55% complex carbohydrates, 30% fat, and 15% protein) will be reduced to obtain a negative balance of 500 kcal/day. Requirements will be calculated by adding the estimated energy expenditure from PA to basal metabolism. Adherence to diet will be verified by the use of food diaries and dietary prescriptions will be adjusted at each intermediate visit. Patients with vitamin D levels ranging from 10 to 20 ng/dl will be treated with cholecalciferol 25.000 IU every 2 weeks for 2 months, then with cholecalciferol 25.000 IU every months, whereas those with vitamin D levels ranging from 20 to 30 ng/dl will be given cholecalciferol 25.000 IU every month. At 6 months participants, will be re-evaluated and treatment will be discontinued in case of vitamin D values \>30 ng/dl or continued for additional 6 months at the doses indicated above, and so on until the end of the study.
Randomization will be stratified by gender (males versus females), age (65-70 versus 71-75) and type of diabetes treatment (non-insulin versus insulin), using a permuted-block randomization software. Physicians and patients will not be blinded to group assignment, at variance with operators executing instrumental procedures, whereas sample blinding at central laboratory will be achieved using bar codes.
The primary endpoint is the trabecular bone score (TBS), which is derived from the antero-posterior spine raw DXA image(s) from the same region of interest as the BMD measurement by the use of a specific software and correlates with three-dimensional bone micro-architecture parameters. Among the numerous potential measures of bone quality, TBS is the only one that has been consistently shown to be lower in T2DM vs. control subjects.
Secondary endpoints include:
1. other potential measures of bone quality as assessed by peripheral quantitative computed tomography (pQCT) and quantitative ultrasound (QUS);
2. bone mass (BMD as assessed by DXA);
3. bone metabolism (sclerostin and other biochemical markers of bone formation and resorption);
4. body composition (total body lean and fat mass by total body DXA);
5. muscle strength (by dynamometer);
6. muscle mass/density (by pQCT);
7. balance, gait and power (by Short Battery Performance Test);
8. musculoskeletal (MS) symptoms (by questionnaire);
h. number of falls (by questionnaire); i. symptomatic and asymptomatic fractures (by history or medical records and vertebral morphometry, respectively).
Other measures include:
* quality of life (QoL);
* cardiorespiratory fitness;
* flexibility;
* volume of PA;
* coronary heart disease 10-year risk score.
Dietary intake and adverse events will be also recorded. Participants from both groups will be followed for additional 5 years in order to record the number of falls and eventual fractures during this time period. PA and MS symptoms will be also monitored throughout this 5-year interval. To this end, patients will be seen yearly (or every 6 months according to the degree of glycemic control and the overall cardiovascular risk profile) in order to collect self-report data on number of falls and type and amount of PA from a daily diary, clinical documentation on eventual fractures, and MS questionnaire.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Type 2 Diabetes
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
SINGLE
Outcome Assessors
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Exercise
Supervised exercise training on top of standard care (exercise, EXE, group; n=100)
Group Type
EXPERIMENTAL
supervised exercise training
Intervention Type
OTHER
Two weekly sessions of 75 min each, supervised by an exercise specialist in a dedicated gym facility. Each session will include: 5 min of warm up; 20 min of aerobic training using treadmill; 15 min of resistance training of muscle groups of skeletal sites of fragility fractures; 15 min of "weight bearing" exercises using weighted vests; 8 min of core stability training; 8 min of balance training; and 4 min of flexibility training. Weighted vest worn also during aerobic training and any occupational, home and leisure-time physical activity.
Control
Standard care including advises to maintain a physically active lifestyle, according to current guidelines, by performing any type of commuting, occupational, home and and leisure-time physical activity (PA) (control, CON, group; n=100).
Group Type
NO_INTERVENTION
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
supervised exercise training
Two weekly sessions of 75 min each, supervised by an exercise specialist in a dedicated gym facility. Each session will include: 5 min of warm up; 20 min of aerobic training using treadmill; 15 min of resistance training of muscle groups of skeletal sites of fragility fractures; 15 min of "weight bearing" exercises using weighted vests; 8 min of core stability training; 8 min of balance training; and 4 min of flexibility training. Weighted vest worn also during aerobic training and any occupational, home and leisure-time physical activity.
Intervention Type
OTHER
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* diabetes duration \>5-year
* sedentary lifestyle (i.e. more than 8 hours/day spent in any waking behavior characterized by an energy expenditure ≤1.5 metabolic equivalents \[METs\] while in a sitting or reclining posture) from at least 6 months;
* physically inactivity (i.e. insufficient amounts of physical activity \[PA\] according to current guidelines) from at least 6 months;
* body mass index (BMI) 27-40 kg/m2;
* ability to walk 1.6 Km without assistance;
* a Short Battery Performance Test score ranging from 4 to 9;
* eligibility after cardiologic evaluation.
* sedentary lifestyle (i.e. more than 8 hours/day spent in any waking behavior characterized by an energy expenditure ≤1.5 metabolic equivalents \[METs\] while in a sitting or reclining posture) from at least 6 months;
* physically inactivity (i.e. insufficient amounts of physical activity \[PA\] according to current guidelines) from at least 6 months;
* body mass index (BMI) 27-40 kg/m2;
* ability to walk 1.6 Km without assistance;
* a Short Battery Performance Test score ranging from 4 to 9;
* eligibility after cardiologic evaluation.
Exclusion Criteria
* any condition limiting participation in a clinical trial, including psychiatric disorders or hospitalization for depression in the past 6 months;
* any condition limiting PA/exercise, including musculoskeletal disorders or deformities, central nervous system dysfunction such as hemiparesis, myelopathies, cerebral ataxia, vestibular dysfunction, and postural hypotension (i.e. a fall of \>20 mmHg of systolic or \>10 mmHg of diastolic blood pressure when changing position);
* cancer and other life-expectancy limiting conditions;
* recent major acute cardiovascular event, including heart attack, stroke/transient ischemic attack(s), revascularization procedure, or participation in a cardiac rehabilitation program within the past three months, or documented history of pulmonary embolism in the past six months;
* pre-proliferative and proliferative retinopathy;
* macroalbuminuria and/or estimated glomerular filtration rate (eGFR) \<45 ml/min/1.73 m2;
* ankle/brachial index (ABI) \<0.9;
* severe motor and sensory neuropathy;
* diabetic foot with history of ulcer;
* hemoglobin (Hb) A1c \>9.0%;
* blood pressure (BP) \>150/90 mmHg;
* vitamin D \<10 ng/ml;
* treatment with anti-fracturative agents, estrogens, aromatase inhibitors, testosterone, corticosteroids and/or glitazon;
* previous documented non-traumatic fractures,
* total spine deformity index (SDI) \>3 (and \>1 in a single vertebra);
* a T score \<-2.5 at spine/hip at dual-energy X-ray absorptiometry (DXA). Subjects with HbA1c or blood pressure above the indicated threshold will be receive appropriate treatment and will be re-evaluated after 3 months. Patients with vitamin D levels \< 10 ng/dl will be treated with cholecalciferol 25.000 IU/week for 6 weeks and will be re-evaluated for eligibility 2 weeks after the last
* any condition limiting PA/exercise, including musculoskeletal disorders or deformities, central nervous system dysfunction such as hemiparesis, myelopathies, cerebral ataxia, vestibular dysfunction, and postural hypotension (i.e. a fall of \>20 mmHg of systolic or \>10 mmHg of diastolic blood pressure when changing position);
* cancer and other life-expectancy limiting conditions;
* recent major acute cardiovascular event, including heart attack, stroke/transient ischemic attack(s), revascularization procedure, or participation in a cardiac rehabilitation program within the past three months, or documented history of pulmonary embolism in the past six months;
* pre-proliferative and proliferative retinopathy;
* macroalbuminuria and/or estimated glomerular filtration rate (eGFR) \<45 ml/min/1.73 m2;
* ankle/brachial index (ABI) \<0.9;
* severe motor and sensory neuropathy;
* diabetic foot with history of ulcer;
* hemoglobin (Hb) A1c \>9.0%;
* blood pressure (BP) \>150/90 mmHg;
* vitamin D \<10 ng/ml;
* treatment with anti-fracturative agents, estrogens, aromatase inhibitors, testosterone, corticosteroids and/or glitazon;
* previous documented non-traumatic fractures,
* total spine deformity index (SDI) \>3 (and \>1 in a single vertebra);
* a T score \<-2.5 at spine/hip at dual-energy X-ray absorptiometry (DXA). Subjects with HbA1c or blood pressure above the indicated threshold will be receive appropriate treatment and will be re-evaluated after 3 months. Patients with vitamin D levels \< 10 ng/dl will be treated with cholecalciferol 25.000 IU/week for 6 weeks and will be re-evaluated for eligibility 2 weeks after the last
Minimum Eligible Age
65 Years
Maximum Eligible Age
75 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Roma La Sapienza
OTHER
Sponsor Role
collaborator
S. Andrea Hospital
OTHER
Sponsor Role
collaborator
Metabolic Fitness Association, Italy
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Giuseppe Pugliese, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Roma La Sapienza
Francesco Conti, MD, PhD
Role: STUDY_DIRECTOR
University of Roma La Sapienza
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
S. Andrea Hospital
Rome, RM, Italy
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Italy
References
Explore related publications, articles, or registry entries linked to this study.
Balducci S, Zanuso S, Cardelli P, Salvi L, Mazzitelli G, Bazuro A, Iacobini C, Nicolucci A, Pugliese G; Italian Diabetes Exercise Study (IDES) Investigators. Changes in physical fitness predict improvements in modifiable cardiovascular risk factors independently of body weight loss in subjects with type 2 diabetes participating in the Italian Diabetes and Exercise Study (IDES). Diabetes Care. 2012 Jun;35(6):1347-54. doi: 10.2337/dc11-1859. Epub 2012 Mar 7.
Reference Type
BACKGROUND
Balducci S, Zanuso S, Nicolucci A, De Feo P, Cavallo S, Cardelli P, Fallucca S, Alessi E, Fallucca F, Pugliese G; Italian Diabetes Exercise Study (IDES) Investigators. Effect of an intensive exercise intervention strategy on modifiable cardiovascular risk factors in subjects with type 2 diabetes mellitus: a randomized controlled trial: the Italian Diabetes and Exercise Study (IDES). Arch Intern Med. 2010 Nov 8;170(20):1794-803. doi: 10.1001/archinternmed.2010.380.
Reference Type
BACKGROUND
Bonds DE, Larson JC, Schwartz AV, Strotmeyer ES, Robbins J, Rodriguez BL, Johnson KC, Margolis KL. Risk of fracture in women with type 2 diabetes: the Women's Health Initiative Observational Study. J Clin Endocrinol Metab. 2006 Sep;91(9):3404-10. doi: 10.1210/jc.2006-0614. Epub 2006 Jun 27.
Reference Type
BACKGROUND
Burghardt AJ, Issever AS, Schwartz AV, Davis KA, Masharani U, Majumdar S, Link TM. High-resolution peripheral quantitative computed tomographic imaging of cortical and trabecular bone microarchitecture in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2010 Nov;95(11):5045-55. doi: 10.1210/jc.2010-0226. Epub 2010 Aug 18.
Reference Type
BACKGROUND
Carnevale V, Romagnoli E, D'Erasmo L, D'Erasmo E. Bone damage in type 2 diabetes mellitus. Nutr Metab Cardiovasc Dis. 2014 Nov;24(11):1151-7. doi: 10.1016/j.numecd.2014.06.013. Epub 2014 Jul 27.
Reference Type
BACKGROUND
Chan MY, Frost SA, Center JR, Eisman JA, Nguyen TV. Relationship between body mass index and fracture risk is mediated by bone mineral density. J Bone Miner Res. 2014 Nov;29(11):2327-35. doi: 10.1002/jbmr.2288.
Reference Type
BACKGROUND
Cousins JM, Petit MA, Paudel ML, Taylor BC, Hughes JM, Cauley JA, Zmuda JM, Cawthon PM, Ensrud KE; Osteoporotic Fractures in Men (MrOS) Study Group. Muscle power and physical activity are associated with bone strength in older men: The osteoporotic fractures in men study. Bone. 2010 Aug;47(2):205-11. doi: 10.1016/j.bone.2010.05.003. Epub 2010 May 11.
Reference Type
BACKGROUND
De Laet C, Kanis JA, Oden A, Johanson H, Johnell O, Delmas P, Eisman JA, Kroger H, Fujiwara S, Garnero P, McCloskey EV, Mellstrom D, Melton LJ 3rd, Meunier PJ, Pols HA, Reeve J, Silman A, Tenenhouse A. Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos Int. 2005 Nov;16(11):1330-8. doi: 10.1007/s00198-005-1863-y. Epub 2005 Jun 1.
Reference Type
BACKGROUND
de Waard EA, van Geel TA, Savelberg HH, Koster A, Geusens PP, van den Bergh JP. Increased fracture risk in patients with type 2 diabetes mellitus: an overview of the underlying mechanisms and the usefulness of imaging modalities and fracture risk assessment tools. Maturitas. 2014 Nov;79(3):265-74. doi: 10.1016/j.maturitas.2014.08.003. Epub 2014 Aug 18.
Reference Type
BACKGROUND
Dobnig H, Piswanger-Solkner JC, Roth M, Obermayer-Pietsch B, Tiran A, Strele A, Maier E, Maritschnegg P, Sieberer C, Fahrleitner-Pammer A. Type 2 diabetes mellitus in nursing home patients: effects on bone turnover, bone mass, and fracture risk. J Clin Endocrinol Metab. 2006 Sep;91(9):3355-63. doi: 10.1210/jc.2006-0460. Epub 2006 May 30.
Reference Type
BACKGROUND
Donnelly E. Methods for assessing bone quality: a review. Clin Orthop Relat Res. 2011 Aug;469(8):2128-38. doi: 10.1007/s11999-010-1702-0.
Reference Type
BACKGROUND
Gonnelli S, Caffarelli C, Nuti R. Obesity and fracture risk. Clin Cases Miner Bone Metab. 2014 Jan;11(1):9-14. doi: 10.11138/ccmbm/2014.11.1.009.
Reference Type
BACKGROUND
Howe TE, Shea B, Dawson LJ, Downie F, Murray A, Ross C, Harbour RT, Caldwell LM, Creed G. Exercise for preventing and treating osteoporosis in postmenopausal women. Cochrane Database Syst Rev. 2011 Jul 6;(7):CD000333. doi: 10.1002/14651858.CD000333.pub2.
Reference Type
BACKGROUND
Janghorbani M, Van Dam RM, Willett WC, Hu FB. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol. 2007 Sep 1;166(5):495-505. doi: 10.1093/aje/kwm106. Epub 2007 Jun 16.
Reference Type
BACKGROUND
Johansson H, Kanis JA, Oden A, McCloskey E, Chapurlat RD, Christiansen C, Cummings SR, Diez-Perez A, Eisman JA, Fujiwara S, Gluer CC, Goltzman D, Hans D, Khaw KT, Krieg MA, Kroger H, LaCroix AZ, Lau E, Leslie WD, Mellstrom D, Melton LJ 3rd, O'Neill TW, Pasco JA, Prior JC, Reid DM, Rivadeneira F, van Staa T, Yoshimura N, Zillikens MC. A meta-analysis of the association of fracture risk and body mass index in women. J Bone Miner Res. 2014 Jan;29(1):223-33. doi: 10.1002/jbmr.2017.
Reference Type
BACKGROUND
Kim JH, Choi HJ, Ku EJ, Kim KM, Kim SW, Cho NH, Shin CS. Trabecular bone score as an indicator for skeletal deterioration in diabetes. J Clin Endocrinol Metab. 2015 Feb;100(2):475-82. doi: 10.1210/jc.2014-2047. Epub 2014 Nov 4.
Reference Type
BACKGROUND
Leslie WD, Aubry-Rozier B, Lamy O, Hans D; Manitoba Bone Density Program. TBS (trabecular bone score) and diabetes-related fracture risk. J Clin Endocrinol Metab. 2013 Feb;98(2):602-9. doi: 10.1210/jc.2012-3118. Epub 2013 Jan 22.
Reference Type
BACKGROUND
Leslie WD, Rubin MR, Schwartz AV, Kanis JA. Type 2 diabetes and bone. J Bone Miner Res. 2012 Nov;27(11):2231-7. doi: 10.1002/jbmr.1759. Epub 2012 Sep 28.
Reference Type
BACKGROUND
Martyn-St James M, Carroll S. Effects of different impact exercise modalities on bone mineral density in premenopausal women: a meta-analysis. J Bone Miner Metab. 2010 May;28(3):251-67. doi: 10.1007/s00774-009-0139-6. Epub 2009 Dec 15.
Reference Type
BACKGROUND
Napoli N, Strotmeyer ES, Ensrud KE, Sellmeyer DE, Bauer DC, Hoffman AR, Dam TT, Barrett-Connor E, Palermo L, Orwoll ES, Cummings SR, Black DM, Schwartz AV. Fracture risk in diabetic elderly men: the MrOS study. Diabetologia. 2014 Oct;57(10):2057-65. doi: 10.1007/s00125-014-3289-6. Epub 2014 Jun 9.
Reference Type
BACKGROUND
Park SW, Goodpaster BH, Strotmeyer ES, de Rekeneire N, Harris TB, Schwartz AV, Tylavsky FA, Newman AB. Decreased muscle strength and quality in older adults with type 2 diabetes: the health, aging, and body composition study. Diabetes. 2006 Jun;55(6):1813-8. doi: 10.2337/db05-1183.
Reference Type
BACKGROUND
Petit MA, Paudel ML, Taylor BC, Hughes JM, Strotmeyer ES, Schwartz AV, Cauley JA, Zmuda JM, Hoffman AR, Ensrud KE; Osteoporotic Fractures in Men (MrOs) Study Group. Bone mass and strength in older men with type 2 diabetes: the Osteoporotic Fractures in Men Study. J Bone Miner Res. 2010 Feb;25(2):285-91. doi: 10.1359/jbmr.090725.
Reference Type
BACKGROUND
Schwartz AV, Hillier TA, Sellmeyer DE, Resnick HE, Gregg E, Ensrud KE, Schreiner PJ, Margolis KL, Cauley JA, Nevitt MC, Black DM, Cummings SR. Older women with diabetes have a higher risk of falls: a prospective study. Diabetes Care. 2002 Oct;25(10):1749-54. doi: 10.2337/diacare.25.10.1749.
Reference Type
BACKGROUND
Schwartz AV, Sellmeyer DE, Ensrud KE, Cauley JA, Tabor HK, Schreiner PJ, Jamal SA, Black DM, Cummings SR; Study of Osteoporotic Features Research Group. Older women with diabetes have an increased risk of fracture: a prospective study. J Clin Endocrinol Metab. 2001 Jan;86(1):32-8. doi: 10.1210/jcem.86.1.7139.
Reference Type
BACKGROUND
Tao B, Liu JM, Zhao HY, Sun LH, Wang WQ, Li XY, Ning G. Differences between measurements of bone mineral densities by quantitative ultrasound and dual-energy X-ray absorptiometry in type 2 diabetic postmenopausal women. J Clin Endocrinol Metab. 2008 May;93(5):1670-5. doi: 10.1210/jc.2007-1760. Epub 2008 Mar 4.
Reference Type
BACKGROUND
Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes--a meta-analysis. Osteoporos Int. 2007 Apr;18(4):427-44. doi: 10.1007/s00198-006-0253-4. Epub 2006 Oct 27.
Reference Type
BACKGROUND
Balducci S, Conti F, Sacchetti M, Russo CR, Argento G, Haxhi J, Orlando G, Rapisarda G, D'Errico V, Cardelli P, Pugliese L, Laghi A, Vitale M, Bollanti L, Zanuso S, Nicolucci A, Pugliese G; SWEET BONE Investigators. Study to Weigh the Effect of Exercise Training on BONE quality and strength (SWEET BONE) in type 2 diabetes: study protocol for a randomised clinical trial. BMJ Open. 2019 Nov 4;9(11):e027429. doi: 10.1136/bmjopen-2018-027429.
Reference Type
DERIVED
Related Links
Access external resources that provide additional context or updates about the study.
http://www.metabolicfitness.it/
Web site of the Metabolic Fitness Association
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MFA-04
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Effects of Frequency and Duration of Exercise in People With Type 1 Diabetes A Randomized Crossover Study
NCT04089462
COMPLETED
NA
The Features Behind the Beneficial Effects of Interval-walking
NCT02257190
COMPLETED
NA
Effects of Exercise Intervention and Rehabilitation Exercise Intervention in Patients With Type 2 Diabetes
NCT01393275
COMPLETED
NA
Secondary Prevention in Type 2 Diabetes: Comparison of Two Different Resistance Exercise Training Protocols
NCT01218256
COMPLETED
PHASE1
Effect of Acute Exercise on Endothelial Function in Patients With Type 1 Diabetes.
NCT01899872
UNKNOWN
NA
Skeletal Muscle Lipid and Insulin Resistance: Effects of Physical Activity and Weight Loss
NCT00766298
COMPLETED
NA
A Randomized Controlled Trial of Exercise Training Among Men With Type 2-diabetes
NCT00666094
COMPLETED
NA
Training, Detraining, Retraining and Glycemic Control in Patients With Type 2 Diabetes
NCT01580475
COMPLETED
NA
Effects of Six Months of Moderate Resistance- Versus Endurance-Training on Muscle ATP Synthesis in First-Degree Relatives of Patients With Type 2 Diabetes
NCT01145092
COMPLETED
NA
Exercise Study to Help Patients Who Have Type 2 Diabetes and Depression.
NCT01024790
COMPLETED
PHASE1
Sequences of Aerobic and Resistance Exercise and Cardio-metabolic Functions in T2D
NCT06145542
COMPLETED
NA
Effects of a Multimodal Exercise Program on Physical Performance and Muscle Function in Middle-aged Patients With T2DM
NCT07255222
RECRUITING
NA
Intensity of Exercise and Glucose Metabolism
NCT01649219
UNKNOWN
PHASE4
Exercise Training Intervention in Children With Type 1 Diabetes
NCT01220479
COMPLETED
NA
Effect of Different Exercises on Musculoskeletal Pain,Glucose Level and Quality of Life Among Patients With Diabetes
NCT03200795
UNKNOWN
NA
A Study of the Effects of Exercise Intensity on Insulin Sensitivity in Overweight Youth
NCT00755547
COMPLETED
PHASE4
Effects Of Resistive Exercise or Proprioceptive Exercise Training Among Patients With Type 2 Diabetes Mellitus
NCT03363386
COMPLETED
NA
Efficacy Study of Standard Ballroom and Latin Dance Program in Type 2 Diabetes and Obesity
NCT02021890
COMPLETED
NA
Effects of Different Types of Exercise in Type 2 Diabetes
NCT01182948
COMPLETED
NA
Diet and Exercise in Type 2 Diabetes - a Randomized Controlled Trial
NCT01513798
COMPLETED
NA
Exercise Training and Type 2 Diabetes
NCT01234155
COMPLETED
NA
The Effects of Metformin on Self-selected Exercise Intensity, Physical Fitness and Exercise-induced AMPK-activation
NCT02951260
COMPLETED
NA
Exercise Effects on Cardiovascular Risk Factors, Quality of Life, Muscle Function in Type 2 Diabetes and Healthy Persons
NCT00852982
UNKNOWN
NA
Exercise Intensity and Type 2 Diabetics
NCT01356953
COMPLETED
NA
Blood Sugar Responses by Physical Activity Level and Intensity
NCT02587780
UNKNOWN